sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
|
IOPIDINE
|
sedatives
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s1
|
DDI-DrugBank.d224.s1.p4
|
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.
|
Nimodipine
|
bosentan
|
NONE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s32
|
DDI-DrugBank.d289.s32.p12
|
Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
|
Epinephrine
|
isoproterenol
|
ADVISE
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s2
|
DDI-DrugBank.d247.s2.p1
|
The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.
|
nitrofurantoin
|
Norfloxacin
|
EFFECT
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s10
|
DDI-DrugBank.d217.s10.p2
|
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
|
tetracyclines
|
aluminum
|
MECHANISM
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s2
|
DDI-DrugBank.d500.s2.p1
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
fentanyl
|
central nervous system depressants
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p23
|
Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.
|
theophylline
|
quinolones
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s0
|
DDI-DrugBank.d562.s0.p0
|
MAO inhibitors prolong and intensify the effects of antihistamines.
|
MAO inhibitors
|
antihistamines
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s0
|
DDI-DrugBank.d448.s0.p0
|
Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)
|
Trileptal
|
AED
|
NONE
|
Oxcarbazepine_ddi.xml
|
DDI-DrugBank.d307.s16
|
DDI-DrugBank.d307.s16.p0
|
Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.
|
Sonata
|
warfarin
|
NONE
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s35
|
DDI-DrugBank.d324.s35.p4
|
Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.
|
fluconazole
|
celecoxib
|
MECHANISM
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s16
|
DDI-DrugBank.d172.s16.p2
|
Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
|
PEGANONE
|
phenacemide
|
ADVISE
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s1
|
DDI-DrugBank.d359.s1.p1
|
Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.
|
phenobarbital
|
exemestane
|
MECHANISM
|
Exemestane_ddi.xml
|
DDI-DrugBank.d435.s2
|
DDI-DrugBank.d435.s2.p9
|
Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.
|
phenytoin
|
dopamine HCl
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s13
|
DDI-DrugBank.d325.s13.p0
|
Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
|
diltiazem hydrochloride
|
propranolol
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s8
|
DDI-DrugBank.d565.s8.p0
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
lovastatin
|
warfarin
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p1
|
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.
|
Folic acid
|
primidone
|
EFFECT
|
Leucovorin_ddi.xml
|
DDI-DrugBank.d151.s0
|
DDI-DrugBank.d151.s0.p2
|
Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
|
Corticosteroids
|
amphotericin B
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s2
|
DDI-DrugBank.d318.s2.p2
|
ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
|
ISUPREL
|
anesthetics
|
ADVISE
|
Isoproterenol_ddi.xml
|
DDI-DrugBank.d55.s2
|
DDI-DrugBank.d55.s2.p0
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
Antihistamines
|
antianxiety agents
|
EFFECT
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p5
|
Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.
|
Macrolide antibiotics
|
corticosteroid
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s3
|
DDI-DrugBank.d314.s3.p2
|
Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.
|
estrogens
|
estrogen
|
NONE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s27
|
DDI-DrugBank.d54.s27.p0
|
Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.
|
alosetron
|
itraconazole
|
ADVISE
|
Alosetron_ddi.xml
|
DDI-DrugBank.d364.s10
|
DDI-DrugBank.d364.s10.p4
|
If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.
|
beta blockers
|
clonidine
|
ADVISE
|
Atenolol_ddi.xml
|
DDI-DrugBank.d73.s5
|
DDI-DrugBank.d73.s5.p5
|
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
|
acetylsalicylic acid
|
benzodiazepines
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s3
|
DDI-DrugBank.d209.s3.p32
|
Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
|
theophylline
|
diuretics
|
NONE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s3
|
DDI-DrugBank.d284.s3.p10
|
It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.
|
laxative
|
CAMPTOSAR
|
EFFECT
|
Irinotecan_ddi.xml
|
DDI-DrugBank.d279.s10
|
DDI-DrugBank.d279.s10.p0
|
Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.
|
digitalis
|
Tiazac
|
EFFECT
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s1
|
DDI-DrugBank.d565.s1.p2
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
narcotics
|
tricyclic antidepressants
|
NONE
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p28
|
Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.
|
Aminoglutethimide
|
corticosteroids
|
EFFECT
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s0
|
DDI-DrugBank.d314.s0.p2
|
However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.
|
metformin
|
Acarbose
|
MECHANISM
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s10
|
DDI-DrugBank.d536.s10.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
buspirone
|
doxycycline
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p224
|
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.
|
carbamazepine
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s18
|
DDI-DrugBank.d314.s18.p10
|
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
|
esomeprazole
|
iron
|
MECHANISM
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s12
|
DDI-DrugBank.d29.s12.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chlorpropamide
|
influenza virus vaccine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p464
|
Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
|
chlorprothixene
|
Ultram
|
ADVISE
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s3
|
DDI-DrugBank.d503.s3.p1
|
This may indicate that ibuprofen could enhance the toxicity of methotrexate.
|
ibuprofen
|
methotrexate
|
EFFECT
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s6
|
DDI-DrugBank.d415.s6.p0
|
Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).
|
verapamil
|
HMG-CoA reductase inhibitor class
|
EFFECT
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s12
|
DDI-DrugBank.d567.s12.p9
|
Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
|
tricyclic antidepressant
|
cimetidine
|
MECHANISM
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s24
|
DDI-DrugBank.d223.s24.p0
|
In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.
|
salicylate
|
ketorolac
|
MECHANISM
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s3
|
DDI-DrugBank.d3.s3.p0
|
However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
|
quinolones
|
theophylline
|
MECHANISM
|
Levofloxacin_ddi.xml
|
DDI-DrugBank.d242.s1
|
DDI-DrugBank.d242.s1.p0
|
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.
|
Warfarin
|
VIOXX
|
NONE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s31
|
DDI-DrugBank.d210.s31.p0
|
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.
|
Isoniazid
|
carbamazepine
|
NONE
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s7
|
DDI-DrugBank.d187.s7.p9
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
diazoxide
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p15
|
In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.
|
anticoagulants
|
INDOCIN
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s7
|
DDI-DrugBank.d82.s7.p0
|
Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
|
neomycin
|
ACTH
|
EFFECT
|
6100240.xml
|
DDI-MedLine.d2.s1
|
DDI-MedLine.d2.s1.p1
|
Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.
|
Chloramphenicol
|
ceftazidime
|
EFFECT
|
Ceftazidime_ddi.xml
|
DDI-DrugBank.d122.s3
|
DDI-DrugBank.d122.s3.p1
|
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
|
Perhexiline hydrogen maleate
|
Bezalip
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s11
|
DDI-DrugBank.d291.s11.p1
|
Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.
|
Colchicine
|
vitamin B12
|
MECHANISM
|
Cyanocobalamin_ddi.xml
|
DDI-DrugBank.d39.s1
|
DDI-DrugBank.d39.s1.p2
|
Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.
|
doxylamine
|
CNS depressant drugs
|
EFFECT
|
Doxylamine_ddi.xml
|
DDI-DrugBank.d387.s0
|
DDI-DrugBank.d387.s0.p2
|
Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.
|
PLETAL
|
erythromycin
|
ADVISE
|
Cilostazol_ddi.xml
|
DDI-DrugBank.d358.s0
|
DDI-DrugBank.d358.s0.p5
|
When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
|
Bezalip retard
|
anticoagulants of the coumarin type
|
EFFECT
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s0
|
DDI-DrugBank.d291.s0.p9
|
Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).
|
tolazamide
|
doxepin
|
EFFECT
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s28
|
DDI-DrugBank.d223.s28.p2
|
Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
|
Benzodiazepines
|
midazolam
|
NONE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s12
|
DDI-DrugBank.d76.s12.p6
|
It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.
|
griseofulvin
|
LEVULAN KERASTICK
|
EFFECT
|
Aminolevulinic acid_ddi.xml
|
DDI-DrugBank.d379.s1
|
DDI-DrugBank.d379.s1.p12
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
zonisamide
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p44
|
Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
|
norethindrone
|
norethindrone
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s19
|
DDI-DrugBank.d382.s19.p19
|
In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.
|
digoxin
|
aminosalicylic acid
|
ADVISE
|
Aminosalicylic Acid_ddi.xml
|
DDI-DrugBank.d22.s1
|
DDI-DrugBank.d22.s1.p0
|
Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.
|
Aprepitant
|
ketoconazole
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s31
|
DDI-DrugBank.d382.s31.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anabolic steroids
|
naproxen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p287
|
CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.
|
itraconazole
|
amphotericin B
|
NONE
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s4
|
DDI-DrugBank.d350.s4.p2
|
A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.
|
BREVIBLOC
|
warfarin
|
NONE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s2
|
DDI-DrugBank.d422.s2.p8
|
Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
|
midazolam
|
indomethacin
|
NONE
|
11210678.xml
|
DDI-MedLine.d67.s0
|
DDI-MedLine.d67.s0.p6
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
phenothiazines
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p14
|
The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.
|
TAMBOCOR
|
propranolol
|
EFFECT
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s6
|
DDI-DrugBank.d87.s6.p0
|
In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.
|
ZEBETA
|
clonidine
|
ADVISE
|
Bisoprolol_ddi.xml
|
DDI-DrugBank.d476.s2
|
DDI-DrugBank.d476.s2.p2
|
Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.
|
Theophylline
|
aminophylline
|
NONE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s26
|
DDI-DrugBank.d76.s26.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anabolic steroids
|
ranitidine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p298
|
Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.
|
Cholestyramine
|
progestins
|
MECHANISM
|
Cholestyramine_ddi.xml
|
DDI-DrugBank.d566.s0
|
DDI-DrugBank.d566.s0.p10
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
antibiotics
|
sulfamethoxazole
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p355
|
The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.
|
diuretic
|
Lotensin
|
ADVISE
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s1
|
DDI-DrugBank.d561.s1.p2
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
terbutaline
|
isoniazid
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p77
|
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
|
Antacids
|
antacid
|
NONE
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s9
|
DDI-DrugBank.d176.s9.p0
|
Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.
|
digitoxin
|
antithyroid agents
|
MECHANISM
|
Carbimazole_ddi.xml
|
DDI-DrugBank.d213.s1
|
DDI-DrugBank.d213.s1.p2
|
When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
|
imidazole compounds
|
coumarin
|
EFFECT
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s19
|
DDI-DrugBank.d458.s19.p1
|
Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
|
Fluvoxamine
|
tolbutamide
|
MECHANISM
|
11180037.xml
|
DDI-MedLine.d99.s0
|
DDI-MedLine.d99.s0.p0
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenylbutazone
|
tolbutamide
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p219
|
- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood
|
methyldopa
|
sulfapyridine
|
EFFECT
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s39
|
DDI-DrugBank.d179.s39.p5
|
In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.
|
Nalfon
|
steroid
|
ADVISE
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s11
|
DDI-DrugBank.d154.s11.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
astemizole
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p4
|
The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.
|
nevirapine
|
warfarin
|
INT
|
Nevirapine_ddi.xml
|
DDI-DrugBank.d270.s9
|
DDI-DrugBank.d270.s9.p1
|
Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.
|
Antidepressants
|
tricyclic
|
NONE
|
Arbutamine_ddi.xml
|
DDI-DrugBank.d253.s3
|
DDI-DrugBank.d253.s3.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
cisapride
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p12
|
Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.
|
Beta blockers
|
clonidine
|
EFFECT
|
Atenolol_ddi.xml
|
DDI-DrugBank.d73.s3
|
DDI-DrugBank.d73.s3.p0
|
Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
|
ENABLEX
|
tricyclic antidepressants
|
ADVISE
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s1
|
DDI-DrugBank.d459.s1.p2
|
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
|
NSAIDs
|
cyclosporine
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s7
|
DDI-DrugBank.d219.s7.p4
|
ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
|
ADL 8-2698
|
morphine
|
EFFECT
|
11180040.xml
|
DDI-MedLine.d87.s0
|
DDI-MedLine.d87.s0.p0
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
NSAIDs
|
Aleve
|
NONE
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p33
|
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.
|
halogenated hydrocarbon anesthetics
|
catecholamines
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s8
|
DDI-DrugBank.d325.s8.p3
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
gallamine
|
Coly-Mycin M
|
EFFECT
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p17
|
Naproxen had no effect on plasma levels of diflunisal.
|
Naproxen
|
diflunisal
|
NONE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s28
|
DDI-DrugBank.d132.s28.p0
|
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
|
spironolactone
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s2
|
DDI-DrugBank.d450.s2.p42
|
Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
|
selective serotonin reuptake inhibitor
|
sumatriptan
|
EFFECT
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s16
|
DDI-DrugBank.d568.s16.p4
|
However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
|
iloprost
|
antihypertensive agents
|
EFFECT
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s1
|
DDI-DrugBank.d549.s1.p1
|
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.
|
warfarin
|
ketorolac tromethamine
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s4
|
DDI-DrugBank.d3.s4.p12
|
Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.
|
Vardenafil
|
ritonavir
|
ADVISE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s15
|
DDI-DrugBank.d198.s15.p0
|
BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
|
tricyclic antidepressants
|
adrenergic agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s6
|
DDI-DrugBank.d284.s6.p9
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
nefazadone
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p66
|
Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.
|
Antihistamines
|
tricyclic antidepressants
|
EFFECT
|
Carbinoxamine_ddi.xml
|
DDI-DrugBank.d389.s0
|
DDI-DrugBank.d389.s0.p0
|
Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.
|
non-depolarizing muscle relaxants
|
piperacillin
|
EFFECT
|
Piperacillin_ddi.xml
|
DDI-DrugBank.d462.s4
|
DDI-DrugBank.d462.s4.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.